Study of EIK1005 for advanced solid tumors
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests an experimental drug called EIK1005, either alone or combined with another drug (pembrolizumab), for people with advanced solid tumors, especially those with MSI-H or dMMR cancers (tumors that have trouble repairing their DNA). The goal is to see if it can shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have a life expectancy of at least 3 months.
- You must have advanced cancer (spread to other parts of the body or cannot be surgically removed).
- You must be able to do most daily activities without significant help (ECOG 0 or 1).
- Your cancer must have progressed after at least one standard treatment, or you cannot tolerate standard treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new drug (EIK1004) designed to block a protein called PARP1, which helps repair DNA. It is for people with advanced solid tumors, especially those with BRCA or other DNA repair gene mutations. The goal is to see if it can shrink tumors or slow their growth.
This trial tests a new drug called JMKX005425 for people with advanced solid tumors that have a specific genetic feature called MSI-H or dMMR. If you have this feature and your cancer has not responded to other treatments, this study may offer a new option.
This trial is testing a new oral medication, VVD-133214, for people with advanced solid tumors that have a specific genetic feature called MSI-high or dMMR. The study will see if the drug is safe and effective when given alone or with other drugs like bevacizumab or pembrolizumab.
This trial tests an experimental pill (FS-207) for people with advanced solid tumors that have a specific genetic marker called MSI-H (high microsatellite instability) or dMMR. If you have already had immunotherapy that didn't work, this drug might help by attacking cancer cells in a new way.
This early-phase study tests GV20-0251 (an anti-cancer treatment) by itself and combined with pembrolizumab, to see how well it works and how safe it is. It is for adults with advanced solid tumors that have grown despite standard treatments, or where standard treatments aren’t an option.
This trial tests a new drug (EIK1001) combined with the standard immunotherapy pembrolizumab (Keytruda) for people with advanced melanoma that cannot be removed by surgery or has spread. The goal is to see if adding EIK1001 is more effective than placebo plus pembrolizumab.
Hear when a new MSI-H/dMMR Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.